| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
We have previously reported that serine proteases were involved in the pathogenesis of chronic kidney disease (CKD) and SP inhibitor (SPI) could have renoprotective effects. We conducted this study to identify serine proteases (SPs) which could be associated with glomerular injuries and to explore therapeutic effects of SP inhibition on glomerular injuries in CKD model rats. Urinary plasmin activity and glomerular plasmin ware increased in CKD model rats accompanied by massive urinary protein, glomerular sclerosis, and glomerular apoptotic cells. The administration of serine protease inhibitors mitigated those changes. Our study suggests that SP inhibition could be a new strategy for the treatment of CKD with glomerular injury/proteinuria.
|
